Sagimet Biosciences Inc. Series A (SGMT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Sagimet Biosciences Inc. Series A (SGMT) is Neutral.

The composite score behind that read is -0.18, weighing +0.25 of bullish evidence against -0.21 bearish.

Sagimet Biosciences Inc. Series A last closed at $9.03, -1.20% on the session.

Against the IVW growth benchmark the position is -2.12% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

15 graded predictions for SGMT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Sagimet Biosciences Inc. Series A in the 23rd percentile on return on equity, where 100 is best.

Sagimet Biosciences Inc. Series A is classified under Health Care / Biotechnology, with a market capitalisation of $644.67M.

StockMap tracks Sagimet Biosciences Inc. Series A as the 152nd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Sagimet Biosciences Inc. Series A ranks 148th of 344 in the group, against a group median of -0.21.